Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"CYNA is now well funded, NASDAQ-listed and liquid; it isdefinitely among my better ideas as of today." (7/8/15) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Jason Napodano More >
James Terwilliger joined The Benchmark Company in January 2012 to cover small- to mid-cap medical device and healthcare services companies. He has more than 10 years of equity research experience covering companies in the cardiology, oncology, orthopedics, technology and service sectors. Previous to working with Benchmark, Terwilliger was the executive managing director of healthcare research at Duncan Williams Inc. His other Wall Street affiliations include Morgan Keegan & Company, Sander Morris Harris Inc. and Needham & Company. Terwilliger's healthcare industry experience includes sales and marketing with Johnson & Johnson Healthcare Systems Inc. and as a healthcare consultant for Ernst & Young. He was also president of Neurorecovery Inc., a biopharmaceutical company focused on neurological conditions. In 2005, Terwilliger was recognized by The Wall Street Journal as an All-Star Analyst for stock price performance for medical devices and equipment. He was also recognized in 2002 by StarMine as one of the top medical device analysts for earnings accuracy. Terwilliger holds a master's degree in public health from Yale School of Medicine with a focus on healthcare management and healthcare finance.
Top Medtech Analyst Points to Post-Obamacare Opportunities (9/6/12) New product visibility is vital in medical device stories. Without something new to show physicians, there is no way to get through the door. Medical Devices and Outsourcing Services Analyst James Terwilliger of The Benchmark Company looks for investments that will pique the interests of cardiologists, orthopedists and long-term care facilities. In this exclusive interview with The Life Sciences Report, Terwilliger shares the names of companies poised to grow as the economy rebounds in the next two years.
"When I can get potential blue-sky regenerative technologies like RP's at this small valuation, I'm buying." (8/12/15) RepliCel Life Sciences Inc. - The Life Sciences Report Interview with Eden Rahim More >